compound introduction
Information DS-1001b (DS 1001) DS-1001b is an oral selective inhibitor of mutant IDH1 R132X with potential antineoplastic activity and is designed to penetrate the blood-brain barrier. Targets IDH1 R132X In vitro DS-1001b impairs the proliferation of IDH1 mutant chondrosarcoma cell lines and decreases 2-HG levels. In vivo Continuous administration of DS-1001b impairs tumor growth in xenograft mice. Cell Research(from reference) Cell lines：JJ012,L835 cell lines Concentrations：0-10µM Incubation Time：72 h
